BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare CV&Met: Duchenne Muscular Dystrophy (DMD) Market Spotlight

February 19, 2020

Duchenne muscular dystrophy (DMD) is a genetic condition caused by a lack of dystrophin (a protein which keeps the muscle cells intact) that leads to gradual muscle degeneration and weakness. It occurs because of a mutation in a gene on the X chromosome that produces dystrophin. Therefore, males have a 50% chance of inheriting the mutation and being affected by the disease, while females have a 50% chance of inheriting the flawed gene and being a carrier. The first symptoms of DMD are generally experienced in early childhood between the age of 3–5 years. The disorder first starts in the muscles of the pelvic region, hips, thighs, and shoulders, later affecting the skeletal muscles in the legs, arms, and trunk. By the time the patient reaches teenage years, the respiratory and cardiac muscles are also affected. Life expectancy for DMD patients (mainly males) varies from the 20s up to the 50s.

This Datamonitor Healthcare report contains a Market Spotlight module.
Indications Covered: Duchenne Muscular Dystrophy (DMD)
Back to the top Back to the top